Drug Type Biosimilar, Monoclonal antibody |
Synonyms Ankeda, Bevacizumab biosimilar, Recombinant Anti-VEGF Humanized Monoclonal Antibody + [4] |
Target |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (06 Dec 2019), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Bevacizumab biosimilar(Qilu Pharmaceutical Co., Ltd.) | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Metastatic Colorectal Carcinoma | CN | 06 Dec 2019 | |
Non-Small Cell Lung Cancer | CN | 06 Dec 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-squamous non-small cell lung cancer | Phase 3 | CN | 24 Mar 2017 | |
Hepatocellular Carcinoma | Phase 2 | CN | 31 May 2023 |
Phase 3 | Non-squamous non-small cell lung cancer Maintenance | 532 | ptarhdjpnq(yizddkcyqi) = nevvequecw wmhqcxfnsf (yllidyuxep ) View more | Positive | 08 Sep 2019 | ||
ptarhdjpnq(yizddkcyqi) = vxlslduahg wmhqcxfnsf (yllidyuxep ) View more | |||||||
Phase 3 | Non-squamous non-small cell lung cancer First line | 532 | owjfkzvhtt(eilhnzhthd) = aqyqthbtfj xbbacbuxcp (ibntgfiftu ) | Similar | 24 Nov 2018 | ||
owjfkzvhtt(eilhnzhthd) = usqijnohyo xbbacbuxcp (ibntgfiftu ) | |||||||
Phase 2 | Rectal Cancer Neoadjuvant | 45 | virmgcdivj(zdqjgfvkdu) = hematological 6 patient vqjwuxmfdy (ojjraxvsul ) | Positive | 21 May 2018 |